← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

ARMEN GARO H

EXEC. CHAIR & PRINCIPAL OFF | EXEC. CHAIR & PRINCIPAL OFF.

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0000935679

Purchase history

Companies traded
1
Purchases · 12M
7
Purchases · 24M
7
Average purchase
$4.4K
Median purchase
$1.3K
Gross purchase value
$30.7K

Companies: Protagenic Therapeutics, Inc. ew

7 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-08-24Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$13.0KOpen filing
2026-08-20Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$9.8KOpen filing
2026-08-20Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$945Open filing
2026-08-12Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$710Open filing
2026-08-10Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$151Open filing
2026-08-06Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF$1.3KOpen filing
2026-08-03Protagenic Therapeutics, Inc. ewPTIXEXEC. CHAIR & PRINCIPAL OFF.$4.7KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
1/7
Large purchase ≥ $100k
0/7
Cluster buying · 15D
0/7
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.